2020
DOI: 10.1007/s00415-020-09942-w
|View full text |Cite
|
Sign up to set email alerts
|

Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
82
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 103 publications
(97 citation statements)
references
References 100 publications
1
82
0
Order By: Relevance
“…Also, Fluorouracil (5-FU) induces increased autophagy in colon cancer cells with p53 deletion or mutation leading to increased drug resistance ( 14 ). Some scholars have studied the effect of autophagy on the efficacy of oxaliplatin and found that L-OHP can induce autophagy in CRC cells to protect CRC cells from apoptosis ( 15 ). Other studies have shown that certain drugs can exert anti-CRC effects by inducing autophagy.…”
Section: Introductionmentioning
confidence: 99%
“…Also, Fluorouracil (5-FU) induces increased autophagy in colon cancer cells with p53 deletion or mutation leading to increased drug resistance ( 14 ). Some scholars have studied the effect of autophagy on the efficacy of oxaliplatin and found that L-OHP can induce autophagy in CRC cells to protect CRC cells from apoptosis ( 15 ). Other studies have shown that certain drugs can exert anti-CRC effects by inducing autophagy.…”
Section: Introductionmentioning
confidence: 99%
“…Acute oxaliplatin‐induced peripheral neuropathy (OIPN) occurs in nearly all patients, and symptoms may appear during or shortly after the first infusions. These transient symptoms are paresthesia triggered by cold and dysesthesias in the perioral region, hands, and feet 7–11 . A varied incidence of 4% to 98%, probably due to different starting doses, drug combinations, dosing intervals, and measurements, is reported 10 .…”
Section: Introductionmentioning
confidence: 99%
“…28,30,32 In 2 other studies (n = 165 patients), CHM had significant positive results after 8 treatment cycles (OR = 0.49, 95% CI = 0.24 to 1.01, P = .05; I ÂČ = 0%; Figure 4). 25,31 CHM also showed a reduction in OIPN incidence compared with warm water bath (n = 55 patients; OR = 0.20, 95% CI = 0.06 to 0.69, P = .01) 28 or mecobalamin (n = 90 patients; OR = 0.18, 95% CI = 0.07 to 0.45, P < .01). 24 One trial (n = 44 patients) 27 compared CHM plus mecobalamin to mecobalamin, demonstrating a difference in favor of CHM plus mecobalamin after 8 and 12 treatment cycles (OR = 0.02, 95% CI = 0.00 to 0.11, P < .01, and OR = 0.23, 95% CI = 0.05 to 1.01, P = .05, respectively).…”
Section: Resultsmentioning
confidence: 90%
“…Overall, most studies reported prespecified outcomes, but only 1 study that did not report expected outcomes was deemed to be at high risk of bias. 28…”
Section: Resultsmentioning
confidence: 99%